An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis
연구 개요
상세 설명
Approximately 120 subjects will be randomized to receive either enteric-coated (EC) LYC-30937-EC 25 mg PO once daily (QD) or matching placebo PO QD for the duration of 8 weeks. Randomization will be stratified based on previous exposure to anti-tumor necrosis factor (TNF) agents such that at least 50% of the randomized subjects will be anti-TNF naïve .
The study will consist of 3 phases:
- screening phase: up to 4 weeks
- double-blind placebo-controlled phase treatment: 8 weeks
- post-treatment follow-up: 2 weeks
Eligible subjects will be randomized at Week 0 (Study Day 1) to either LYC-30937-EC 25 mg or placebo. Screening will occur from Study Days -28 to -1. Randomization and first dosing will occur at Week 0/Study Day 1. Double-blind study visits will occur at Weeks 2, 4, and 8, with the last dose at Week 8/Study Day 57. Subjects will return at Week 10 for a post-treatment safety follow-up visit.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Amsterdam, 네덜란드, 1081 HZ
- Lycera Investigational Site
-
Rotterdam, 네덜란드, 3015 CE
- Lycera Investigational Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72212
- Lycera Investigational Site
-
-
California
-
Long Beach, California, 미국, 90822
- Lycera Investigational Site
-
Mission Hills, California, 미국, 91345
- Lycera Investigational Site
-
Rialto, California, 미국, 92377
- Lycera Investigational Site
-
-
Florida
-
Hollywood, Florida, 미국, 33021
- Lycera Investigational Site
-
Miami, Florida, 미국, 33176
- Lycera Investigational Site
-
-
Georgia
-
Decatur, Georgia, 미국, 30033
- Lycera Investigational Site
-
Marietta, Georgia, 미국, 30060
- Lycera Investigational Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- Lycera Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- Lycera Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70809
- Lycera Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- Lycera Investigational Site
-
-
New York
-
Bronx, New York, 미국, 10461
- Lycera Investigational Site
-
Brooklyn, New York, 미국, 11230
- Lycera Investigational Site
-
New York, New York, 미국, 10024
- Lycera Investigational Site
-
-
North Carolina
-
Greenville, North Carolina, 미국, 27834
- Lycera Investigational Site
-
-
Pennsylvania
-
Flourtown, Pennsylvania, 미국, 19031
- Lycera Investigational Site
-
Philadelphia, Pennsylvania, 미국, 19104
- Lycera Investigational Site
-
Sayre, Pennsylvania, 미국, 18840
- Lycera Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37212
- Lycera Investigational Site
-
Union City, Tennessee, 미국, 38261
- Lycera Investigational Site
-
-
Texas
-
Houston, Texas, 미국, 77030
- Lycera Investigational Site
-
Houston, Texas, 미국, 76092
- Lycera Investigational Site.
-
Houston, Texas, 미국, 77004
- Lycera Investigational Sites
-
Houston, Texas, 미국, 77004
- Lycera Investigational Site
-
San Antonio, Texas, 미국, 78229
- Lycera Investigational Site
-
-
-
-
-
Belgrade, 세르비아, 11000
- Lycera Investigational Site
-
Belgrade, 세르비아, 11080
- Lycera Investigational Site
-
Kragujevac, 세르비아, 34000
- Lycera Investigational Site
-
Niš, 세르비아, 18000
- Lycera Investigational Site
-
Subotica, 세르비아, 24000
- Lycera Investigational Site
-
Zrenjanin, 세르비아, 23000
- Lycera Investigational Site
-
-
-
-
-
Ostrava, 체코, 722 00
- Lycera Investigational Site
-
Praha, 체코, 130 00
- Lycera Investigational Site
-
Praha 3, 체코, 130 00
- Lycera Investigational Site
-
Slany, 체코, 274 01
- Lycera Investigational Site
-
Usti nad Labem, 체코, 401 13
- Lycera Investigational Site
-
-
-
-
British Columbia
-
Victoria, British Columbia, 캐나다, V8V 3M9
- Lycera Investigational Site
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 1X5
- Lycera Investigational Site
-
-
-
-
-
Bydgoszcz, 폴란드, 85-168
- Lycera Investigational Site
-
Bydgoszcz, 폴란드, 85-681
- Lycera Investigational Site
-
Katowice, 폴란드, 40-211
- Lycera Investigational Site
-
Katowice, 폴란드, 40-659
- Lycera Investigational Site
-
Katowice, 폴란드, 40-752
- Lycera Investigational Site
-
Kielce, 폴란드, 25 364
- Lycera Investigational Site
-
Krakow, 폴란드, 30-415
- Lycera Investigational Site
-
Krakow, 폴란드, 31-009
- Lycera Investigational Site
-
Ksawerów, 폴란드, 95-054
- Lycera Investigational Site
-
Lublin, 폴란드, 20-362
- Lycera Investigational Site
-
Lublin, 폴란드, 20-008
- Lycera Investigational Site
-
Nowa Sól, 폴란드, 67-100
- Lycera Investigational Site
-
Piaseczno, 폴란드, 05-500
- Lycera Investigational Site
-
Poznan, 폴란드, 61-113
- Lycera Investigational Site
-
Skierniewice, 폴란드, 96-100
- Lycera Investigational Site
-
Sopot, 폴란드, 81-756
- Lycera Investigational Site
-
Staszów, 폴란드, 28-200
- Lycera Investigational Site
-
Szczecin, 폴란드, 71-270
- Lycera Investigational Site
-
Warszawa, 폴란드, 02-507
- Lycera Investigational Site
-
Warszawa, 폴란드, 04-749
- Lycera Investigational Site
-
Wloclawek, 폴란드, 87-800
- Lycera Investigational Site
-
Wroclaw, 폴란드, 50-053
- Lycera Investigational Site
-
Wroclaw, 폴란드, 54-144
- Lycera Investigational Site
-
Wrocław, 폴란드, 53-333
- Lycera Investigational Site
-
Wrocław, 폴란드, 50-449
- Lycera Investigational Site
-
Łódź, 폴란드, 93-034
- Lycera Investigational Site
-
-
-
-
-
Budapest, 헝가리, 1088
- Lycera Investigational Site
-
Budapest, 헝가리, 1125
- Lycera Investigational Site
-
Debrecen, 헝가리, 4031
- Lycera Investigational Site
-
Debrecen, 헝가리, 4032
- Lycera Investigational Site
-
Hatvan, 헝가리, 3000
- Lycera Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Clinical UC diagnosis ≥ 6 months prior to screening with minimum disease extent of ≥ 15cm from anal verge.
- Active UC defined as a TMS of 4-11 (inclusive) with endoscopic subscore of ≥ 2 and rectal bleeding subscore of ≥ 1 at screening.
- Females of childbearing potential must have a negative pregnancy test at screening and baseline visits and must agree to use acceptable methods of birth control while in the trial and for 30 days after taking the last dose of study drug.
- May be currently receiving treatment with oral aminosalicylates (ASA) for ≥ 6 weeks at a stable dose for ≥ 3 weeks prior to the screening screening endoscopy and/or thiopurine at a stable dose ≥ 8 weeks prior to the screening endoscopy and/or prednisone (dose 20 mg daily) or equivalent for ≥ 4 weeks and receiving stable dose for ≥ 2 weeks prior to screening endoscopy
- able to provide written informed consent and be compliant with study procedures.
Exclusion Criteria:
- History of Crohn's disease (CD) or indeterminate colitis or the presence or history of fistula consistent with CD.
- Presence of colon polyps.
- Severe extensive disease that in the investigators discretion is likely to require colonic surgery during the 8 week double-blind portion of the trial (eg, fulminant colitis, toxic megacolon, bowel perforation, evidence of acute abdomen).
- History of alcohol or drug abuse within 1 year of randomization.
- History of cancer including solid tumors and hematological malignancies (except basal cell and in situ squamous cell carcinomas of the skin that have been adequately treated with no recurrence for ≥ 1 year prior to screening.
- History or currently active primary or secondary immunodeficiency.
- Clinically relevant hepatic, neurologic, pulmonary, ophthalmological, gastrointestinal, endocrine, psychiatric, or other major systemic disease making implementation of the study difficult or that would put the subject at risk by participating in the study
- Positive test for Clostridium difficile or positive stool culture for enteric pathogens or presence of ova or parasites at screening.
- Liver function tests > 1.5 x upper limit of normal (ULN) or direct bilirubin > 1.5 x ULN
- Hemoglobin < 8.5 g/dl
- Neutrophils < 1500/mm3
- White blood cell (WBC) count < 3000/mm3
- Platelets < 80000 mm3
- International normalized ratio (INR) > 1.5
- Treatment with an immunosuppressant agent within 8 weeks of screening.
- Previous exposure to ≥ 2 approved or investigational biologic agents to treat UC.
- History of UC treatment with a biologic agent within 12 weeks of screening.
- Treatment with rectal steroids within 2 weeks of screening.
- Treatment with an investigational agent within 30 days of screening.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: LYC-30937-EC 25 mg PO QD
LYC-30937-EC 25 mg by mouth once daily for 8 weeks
|
|
|
위약 비교기: Placebo PO QD
Matching placebo by mouth once daily for 8 weeks
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Subjects Who Achieve Clinical Remission at Week 8 Using Modified Mayo Score.
기간: 8 weeks
|
The modified Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 9 points and consists of 3 subscores (stool frequency, rectal bleeding, endoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical remission on the modified Mayo score was defined as a Mayo stool frequency subscore of ≤ 1, Mayo rectal bleeding subscore of 0 and a Mayo endoscopy subscore of ≤ 1. |
8 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Subjects Who Achieve Clinical Remission at Week 8 Using the Total Mayo Score.
기간: 8 weeks
|
The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical remission on the total Mayo Score is defined as a total Mayo score of ≤ 2, with no individual subscore > 1. |
8 weeks
|
|
Number of Subjects With a Clinical Response on the Modified Mayo Score at Week 8.
기간: 8 weeks
|
The modified Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 9 points and consists of 3 subscores (stool frequency, rectal bleeding, endoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical response on the modified Mayo score at Week 8 was defined as a reduction from the baseline modified Mayo score of ≥ 2 points and ≥ 25%, and a decrease from baseline in rectal bleeding score of ≥ 1 point or absolute rectal bleeding score of ≤ 1 point. |
8 weeks
|
|
Number of Subjects With a Clinical Response on the Total Mayo Score at Week 8.
기간: 8 weeks
|
The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical response on the total Mayo score at Week 8 was defined as a reduction from baseline total Mayo score of ≥ 3 points and ≥ 30%, and a decrease from baseline in rectal bleeding score of ≥ 1 point or absolute rectal bleeding score of ≤ 1 point. |
8 weeks
|
|
Percent Change From Baseline to Week 8 in Fecal Calprotectin in Subjects With Baseline Fecal Calprotectin ≥ 250 µg/g
기간: Baseline to Week 8
|
Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation.
|
Baseline to Week 8
|
|
Percent Change From Baseline in Total Mayo Score at Week 8.
기간: Baseline to Week 8
|
Analyzes the change in total Mayo score score between baseline and Week 8 for all randomized subjects who had total Mayo score scores at both baseline and Week 8. The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. |
Baseline to Week 8
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Subjects With Type of Adverse Events (AEs) Serious Adverse Events (SAEs) and AEs That Led to Discontinuation of Treatment.
기간: 10 weeks
|
Adverse events (AEs) were collected from the time a subject signed the informed consent.
Treatment-emergent adverse events (TEAEs) are AEs occurring or worsening after the first dose of study drug (LYC-30937-EC 25 mg or placebo).
Adverse event severity was assessed by the Investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03, with grading as follows: Grade 1 = mild (asymptomatic or mild symptoms), Grade 2 = moderate (minimal, local intervention, or noninvasive intervention indicated); Grade 3 = severe (or medically significant but not life-threatening); Grade 4 = life-threatening; Grade 5 = death.
|
10 weeks
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .